Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis

Paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin shows favorable results in hepatitis C virus genotype 1 (HCV-1) patients in terms of safety and efficacy, but real-world data remain limited for those with advanced hepatic fibrosis (fibrosis 3, F3) or compensated cir...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chun-Hsien, Chen, Chien-Hung, Lin, Chih-Lang, Lin, Chun-Yen, Hu, Tsung-Hui, Tung, Shui-Yi, Hsieh, Sen-Yung, Lu, Sheng-Nan, Chien, Rong-Nan, Hung, Chao-Hung, Sheen, I-Shyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506536/
https://www.ncbi.nlm.nih.gov/pubmed/31068655
http://dx.doi.org/10.1038/s41598-019-43554-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506536/
https://www.ncbi.nlm.nih.gov/pubmed/31068655
http://dx.doi.org/10.1038/s41598-019-43554-3

Ejemplares similares